Comparative Analysis of Tirzepatide and Semaglutide for Managing Obesity, Glycemic Control, and Cardiovascular Outcomes: A Review of Clinical Evidence - Takeaways - MDSpire

Comparative Analysis of Tirzepatide and Semaglutide for Managing Obesity, Glycemic Control, and Cardiovascular Outcomes: A Review of Clinical Evidence

  • By

  • Maan H. Harbi

  • Ahmad M. Ashour

  • Nasser M. Alorfi

  • Mohammed M. Aldurdunji

  • Saad M. Wali

  • Yahya A. Alzahrani

  • April 22, 2026

  • 0 min

Share

  • 1

    Tirzepatide shows greater reductions in body weight and HbA1c compared to semaglutide in individuals with obesity or type 2 diabetes.

  • 2

    Semaglutide has the strongest evidence for cardiovascular risk reduction from trials like SUSTAIN-6 and SELECT.

  • 3

    The SURPASS-CVOT trial confirmed cardiovascular non-inferiority of tirzepatide compared to dulaglutide.

  • 4

    Real-world studies indicate heterogeneous cardiovascular outcomes for both tirzepatide and semaglutide.

  • 5

    Treatment selection between tirzepatide and semaglutide should be individualized based on patient characteristics and clinical priorities.

Original Source(s)

Comparative Analysis of Tirzepatide and Semaglutide for Managing Obesity, Glycemic Control, and Cardiovascular Outcomes: A Review of Clinical Evidence

  • by Maan H. Harbi, Ahmad M. Ashour, Nasser M. Alorfi, Mohammed M. Aldurdunji, Saad M. Wali, Yahya A. Alzahrani

  • April 22, 2026

Related Content

Waist-to-height ratio for OSA risk: a comparative analysis of NHANES and a clinical data

Metabolic and bariatric surgery in mild obesity: mid-term outcomes and safety in an Asian population

Can Uric Acid Distinguish Lipedema From Overweight?

Metabolomics analysis identified higher uric acid levels in patients with lipedema and lymphedema, although associations weakened following adjustment for renal insufficiency.